We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed at $33.39 in the latest trading session, marking a -1.62% move from the prior day. The stock's change was less than the S&P 500's daily gain of 1.18%. Meanwhile, the Dow experienced a rise of 0.59%, and the technology-dominated Nasdaq saw an increase of 2.07%.
The company's stock has climbed by 29.79% in the past month, exceeding the Medical sector's gain of 7.96% and the S&P 500's loss of 2.9%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of -$0.06, down 135.29% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $689.49 million, up 26.55% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.23 per share and a revenue of $2.9 billion, indicating changes of -143.4% and +23.72%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Hims & Hers Health, Inc. is currently a Zacks Rank #5 (Strong Sell).
In terms of valuation, Hims & Hers Health, Inc. is presently being traded at a Forward P/E ratio of 646.48. This denotes a premium relative to the industry average Forward P/E of 27.78.
It's also important to note that HIMS currently trades at a PEG ratio of 48.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Info Systems was holding an average PEG ratio of 2.09 at yesterday's closing price.
The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 110, placing it within the top 46% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know
Hims & Hers Health, Inc. (HIMS - Free Report) closed at $33.39 in the latest trading session, marking a -1.62% move from the prior day. The stock's change was less than the S&P 500's daily gain of 1.18%. Meanwhile, the Dow experienced a rise of 0.59%, and the technology-dominated Nasdaq saw an increase of 2.07%.
The company's stock has climbed by 29.79% in the past month, exceeding the Medical sector's gain of 7.96% and the S&P 500's loss of 2.9%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of -$0.06, down 135.29% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $689.49 million, up 26.55% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.23 per share and a revenue of $2.9 billion, indicating changes of -143.4% and +23.72%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Hims & Hers Health, Inc. is currently a Zacks Rank #5 (Strong Sell).
In terms of valuation, Hims & Hers Health, Inc. is presently being traded at a Forward P/E ratio of 646.48. This denotes a premium relative to the industry average Forward P/E of 27.78.
It's also important to note that HIMS currently trades at a PEG ratio of 48.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Info Systems was holding an average PEG ratio of 2.09 at yesterday's closing price.
The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 110, placing it within the top 46% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.